isonicotinamide has been researched along with Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida, AA; Boroni, M; Bressan, GC; Caetano, MMM; de Andrade Barros, MV; de Oliveira Santos, L; de Oliveira, LL; de Paiva, JC; de Souza, APM; do Vale, JA; Fietto, JLR; Gonçalves, VHS; Guimarães, GR; Machado-Neves, M; Martim, FRG; Moreira, GA; Silva, LVG; Silva-Júnior, A; Teixeira, RR | 1 |
1 other study(ies) available for isonicotinamide and Melanoma
| Article | Year |
|---|---|
The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice.
Topics: Animals; Humans; Immunity; Melanoma; Mice; Niacinamide; Piperidines; Protein Serine-Threonine Kinases; Skin Neoplasms; Tumor Microenvironment | 2022 |